Heim5CV • FRA
add
CureVac BV
Við síðustu lokun
2,57 €
Dagbil
2,58 € - 2,63 €
Árabil
2,06 € - 5,75 €
Markaðsvirði
628,08 m. USD
Meðalmagn
17,27 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
CNBC
fyrir 21 klukkustund
U.S. SEC gives green light for options listing for spot bitcoin ETFs to NYSE
0,094%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 14,44 m. | 90,47% |
Rekstrarkostnaður | 44,97 m. | -16,67% |
Nettótekjur | -72,54 m. | -7,61% |
Hagnaðarhlutfall | -502,51 | 43,51% |
Hagnaður á hvern hlut | -0,32 | -6,67% |
EBITDA | -66,13 m. | 0,71% |
Virkt skatthlutfall | -1,83% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 202,52 m. | -62,35% |
Heildareignir | 556,84 m. | -38,09% |
Heildarskuldir | 180,30 m. | -28,00% |
Eigið fé alls | 376,53 m. | — |
Útistandandi hlutabréf | 224,31 m. | — |
Eiginfjárgengi | 1,53 | — |
Arðsemi eigna | -28,56% | — |
Ávöxtun eigin fjár | -39,45% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -72,54 m. | -7,61% |
Handbært fé frá rekstri | -89,11 m. | -38,99% |
Reiðufé frá fjárfestingum | -7,49 m. | 47,30% |
Reiðufé frá fjármögnun | -1,22 m. | -1,67% |
Breyting á handbæru fé | -97,64 m. | -22,67% |
Frjálst peningaflæði | -74,99 m. | -514,20% |
Um
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Framkvæmdastjóri
Stofnsett
2000
Vefsvæði
Starfsfólk
1.086
